Change the World
via Regenerative Medicines

Starting from Cardiovascular disease, which is the No.1 killer worldwide, putting the patients at the center of everything we do, we will open the door of intractable disease treatment with regenerative medicines

“Remuscularization”
…Next-gen RM into clinical stage

iPSC derived cardiomyoctyes engraft to the host myocardium for a long-term and generate contractile power in stead of failing heart..Fundamental approach that is totally different from existing therapies.

VIEW PIPELINE

One breakthrough technology is not enough

To deliver safe and effective next-generation regenerative medicine, we've developed platform technologies in every step needed by pursuing originality in science

VIEW TECHNOLOGY

featured media

NEWS

20241114

Media CEO Keiichi Fukuda Interviewed by BiotechTV

2024115

Seminar The speech given by CEO Keiichi Fukuda at the Nikkei Forum "Investing in Japanese Regenerative Medicine", held on September 17, 2024, has been posted on the NIKKEI ASIA website.

20241021

Congress Heartseed COO Kikuo Yasui is Speaking at the "2nd Cell & Gene Tech Investment Forum" in South Korea on October 25.

VIEW ALL

IR NEWS

VIEW ALL

PIPELINE

Believe in the power of true regenerative medicine

Lead Pipeline: HS-001

Lead Pipeline

Strategy: Cardiovascular disease is the leading cause of death, and Heart Failure with reduced Left Ventricular Ejection Fraction (LVEF) is the major one. We believe transplanting sufficient number of ventricular cardiomyocytes is the best possible approach to cure Heart Failure with Reduced Ejection Fraction (HFrEF).

Target indication: Target indication is HFrEF, including Dilated Cardiomyopathy (DCM), Old Myocardial Infraction (OMI) and Dilated phase of Hypertrophic Cardiomyopathy (D-HCM)

Product: allogeneic iPSC-derived cardiomyocytes

Route of Administration: Intramyocardial Injection


Research activities for following compounds

Other than our lead pipeline HS-001, intramyocardial injection of allogeneic iPSC-derived cardiomyocytes, researches are ongoing such as using autologous iPSC and HLA knock-out iPSC, which are free of immune rejection. We are also conducting research with a partner to develop more convenient injection methodologies that can be used in wide range of institutions.

TECHNOLOGY

rooted in cutting-edge science
rooted in cutting-edge science

MANAGEMENT

Keiichi FUKUDA

Keiichi FUKUDA, MD/PhD/FACC

Founder and Chief Executive Officer,
Representative Director of the Board
    • 1987
    • PhD in Clinical Cardiology, Keio University Graduate School of Medicine
    • 1991
    • Growth Factor Division, National Cancer Center Research Institute
    • 1992
    • Dept of Mol. Medicine, Beth Israel Hospital, Harvard Medical School
    • 1994
    • Cardiovascular Research Center, University of Michigan
    • 1995
    • Lecturer, Department of Cardiology, Keio University School
    • 1999
    • Associate Professor, Institute for Advanced Cardiac Therapeutics, Keio University
    • 2005
    • Professor, Dept of Regenerative Medicine, Keio University
    • 2010
    • Professor, Department of Cardiology, Keio University
    • 2015
    • Founded Heartseed Inc.
Kikuo YASUI

Kikuo YASUI

Chief Operating Officer,
Director of the Board

Mr. Yasui joined Heartseed in 2019 as COO. Before joining Heartseed, he held various positions with increasing responsibilities at AbbVie /Abbott Japan, including Business Unit Manager, Immunology and Group Manager, Market Access. He also worked at Bain. He graduated from the Univ. of Tokyo, Pharmaceutical Sciences. (MSc)